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Glycobiology is an expanding discipline. Nowhere is this more apparent than in our understanding
of the immune response. Perhaps the title of this focused research topic should be: “Carbohy-
drates: now the sweet spot of immunity!” The revolution in thinking to embrace the “glyco”
component of glycoproteins and glycolipids has been accompanied by the development of new
technologies that allow the structure of many different glycans to be determined. The article by van
Kooyk et al. provides an introduction to glycan analytical tools (1). These range from technically
simple analyses using plant lectins combined with flow cytometry or ELISA methods to obtain
clues of glycan structures, to more complex sequencing methodologies for detailed structural
characterizations. Nevertheless, determining the structure of some glycans, and particularly the
glycosaminoglycans (GAGs), is still extremely difficult. However, good progress is beingmade in this
area (2).
Cell surface glycosylation is a characteristic of all living cells (3, 4), thus it is logical that glycan
structures are involved in self or non-self recognition. Nevertheless, glycans have been excluded
from the thinking of most immunologists. Probably a lack of appreciation of the specificity of
carbohydrate–protein interactions and the diversity of glycan structures led to this outcome. Yet, it
is glycan diversity that has been harnessed bymicrobes to coat their surfaces, andmost immunogens
onmicrobes are glycans. As pathogens developed their glycan coats their vertebrate and invertebrate
hosts similarly developed molecules to recognize these structures. The idea that invertebrate lectins
can recognize glycan structures onmicrobes, thereby facilitatingmicrobe phagocytosis, was accepted
decades ago (5), but the fundamental contribution of glycan–protein interactions to mammalian
immunity was accepted only recently. Numerous molecules involved in invertebrate host defense
that recognize a spectrum of glycan structures on bacteria, fungi, and other pathogens are clearly
related to similarly acting proteins in modern mammals (6). The lectin pathway of complement,
toll-like receptors, the pentraxin pattern recognition receptors, and the galectins all probably arose
initially in invertebrates ancestors and had roles in self or non-self recognition.Wenowknowglycans
and their binding proteins contribute to all aspects of immunology. It was argued that the essential
role glycan–protein binding events play in host defense and infection is the driver of glycan diversity
(3, 4). The evolutionary selection pressures imposed by the need of pathogens to avoid recognition
by the proteins of their host’s immune system, and for hosts to rapidly evolve glycan structures that
are not sites for pathogen adhesion and infection, it was proposed, led to the conservation of glycan
structural diversity (3, 4).
An appreciation of carbohydrate structural diversity is obtained when the number of genes
involved in glycan biosynthesis is appreciated. van Kooyk et al. revealed that if all the genes
involved in glycan biosynthesis are considered they would comprise around 3–4% of the genome
(1). Although they primarily encode enzymes, co-factors, transporters, and activated sugar donors
are also involved. Regulation of the expression of these genes, regulation of the activity of the
different glycosyltransferases through a diverse collection of mechanisms, coupled with regulation
of the expression of core proteins adds an extra dimension to glycoconjugate structural diversity (1).
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Given glycan biosynthetic processes, it is not surprising that gly-
can structures are altered in response to physiological and patho-
logical cues, and these different structures affect the immunolog-
ical outcomes of the process in which they are involved.
Dendritic cell (DC) sialic acids illustrate how glycan struc-
tures can influence the adaptive immune response. Glycans, both
N- and O-linked, on glycoproteins terminate in sialic acid, and
glycolipid gangliosides contain one or more sialic acids. Sialic
acids shield host cells from pathogens, prevent the deposition of
complement components on DCs, and interact with receptors of
the Siglec and Selectin families (7). As explained by Crespo et al.,
the concentration of sialic acids on DCs is very high, most Siglecs
binding to sialic acids on the same DC (i.e., cis interactions) (7).
Sialidase activity releases these Siglecs allowing them to engage in
interactions with sialic acids on pathogens. The balance between
cell surface sialic acid and sialidases may regulate key DC func-
tions like phagocytosis, micropinocytosis, migration, and DC–T
cell interactions (7). Not all leukocytes can have these high-sialic
acid levels, nor can their Siglecs signal via sialic acid in cis inter-
actions. As the binding of Siglecs on eosinophils and neutrophils
to antibodies or multimeric glycan ligands triggers cell death (8),
yet in certain inflammatory conditions, these cell types abound;
this could not happen if these cells have high-sialic acid levels that
bind Siglecs in cis to trigger cell death. Nevertheless, inhibitory
intracellular signals upon Siglec binding sialylated antigens are
common, because most Siglecs have inhibitory ITIM signaling
motifs and DCs may become tolerogenic if their Siglecs recognize
sialylated carbohydrate antigens in tumors (7).
Dendritic cell immunogenicity is also regulated by other car-
bohydrate–protein interactions; the interaction of galectin-1 with
DCs encourages a tolerogenic phenotype (9). Galectins are a fam-
ily of β-galactoside binding lectins. Various galectin family mem-
bers have been described as “regulators of immune homeostasis,”
as “pattern recognition receptors,” and as “receptors for microbial
adhesion and infection” (10). Often there is evidence for the same
galectin having opposing functions, the question is how? Baum
et al. examined the opposing roles of galectins in microbe–host
interactions (11). They described howgalectins can bridge specific
glycans on viral and bacterial pathogens with glycans on target
cell plasma membranes, to increase pathogen attachment. The
outcome of galectin–pathogen interactions is not always infection;
rather there are numerous examples of galectins contributing to
innate and adaptive immune responses to pathogens, and some
galectins have direct microbicidal activity (11). The response
is dependent on the galectin, the pathogen and the host cell,
with factors such as glycan density, glycan clustering, and the
glycoprotein or glycolipid upon which the glycan is presented,
all contributing to the context-specific outcome. Differences in
the N-glycans of resting and activated cytolytic T lymphocytes
(CTLs), with more galectin-3 ligands being present on activated
CTLs, is an example where the density of a glycan structure
regulates CTL function. In a galectin-3 rich milieu (e.g., a tumor),
reduced motility of galectin-3 cross-linked glycoproteins on acti-
vated infiltrating CTLs could explain the decreased CTL activity
within tumors (12).
Involvement in the immune response is also in the functional
realm of GAGs. Simon Davis and Parish highlight the number of
proteins that have heparin/heparan sulfate (HS) binding motifs
within their sequences (13). Many of the possible newHS–protein
interactions that they discovered may act in immune responses
but this is unconfirmed.Other confirmedHS–protein interactions
have clear implications for immunity; described are examples of
HS–protein interactions contributing to (1) cell adhesion and
migration, (2) the regulation of cytokine and chemokine func-
tions, and (3) the sensing of tissue injury (13). The regulation,
by HS, of complement pathway triggered inflammation is empha-
sized by two articles. Perkins et al. used molecular modeling
and affinity coefficient data to develop a bivalent, co-operative
model of complement factor H (CFH) binding to HS (14). They
argued, mutations in either of the CFH HS binding regions that
weaken binding, alters the orientation of CFH on the cell sur-
face disrupting C3b binding and the regulation of C3b activity,
with the result being inflammatory damage, whereas, Clark et al.
offered the opinion that different HS structures (or “postcodes”)
in the glycomatrix of different tissues determine the levels of
immobilized CFH. Probably, both explanations apply and col-
lectively they explain the disease association of CFH polymor-
phisms (15).
The association of GAGs with inflammation extends beyond
complement pathway regulation. Chemokine–HS interactions are
known to establish chemokine gradients to direct leukocytes to
inflammatory sites (16); but the contribution of the HS enzyme,
heparanase (Hpse), to inflammatory disease is under appreciated.
Heparanase assists leukocyte migration across basement mem-
branes by acting as a “path-maker”; however, in type 1 diabetes
Hpse activity actually drives the disease process (17). Simeonovic
et al. describe how within pancreatic islets there are extraordinar-
ily high levels of HS; this HS is essential for beta-cell survival.
If active Hpse degrades HS in the islet basement membrane,
inflammatory mononuclear cells can enter the islet; Hpse from
these cells destroys intra-islet HS, triggering beta-cell death, and
destructive insulitis. The ubiquitous non-sulfated GAG, hyaluro-
nan (HA) is also involved in inflammation. Normally, it has a
very high-average molecular weight, but at sites of inflammation
and tissue injury HA polymers of overlapping length and function
occur. As explained by Petrey and de la Motte, HA can promote
and suppress inflammation, functions that depend upon polymer
length and the activities of HA-binding proteins (18). The ability
of hyaluronidases to degrade HA depends on the conformation
of HA chains, which is influenced by the degree and hierar-
chy of protein–HA interactions, both of which depend on the
HA-binding proteins in the microenvironment (18). The tissue
microenvironment, its carbohydrates and their binding proteins,
underpins the regulation of inflammation by HA and HS in a
range of diseases including type 1 diabetes (18, 19).
The contribution of HS to human immunodeficiency virus
(HIV-1) infection has come of age. Connell and Lortat-Jacob
indicate how the elegant design of a potential drug developed
through an appreciation of themolecular events involved inHIV-1
infection of CD4+ leukocytes (20). Although the surface exposed
V3 loop of the virus protein, gp120, is involve in HS binding, prior
CD4 binding was found to induce a HS binding site that is also
involved in binding toHIV-1’s co-receptors, CXCR4orCCR5. The
glycoconjugate drug candidate was designed to block HIV from
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binding to cell surfaceHS, its co-receptor andCD4. It is composed
of a small CD4 mimetic linked to a chemically synthesized HS
dodecamer (20). This glycoconjugate had strong anti-viral activity
against HIV-1 regardless of its co-receptor usage, which is a major
advance.
These articles highlight the contribution of glycans to different
aspects of the immune response, yet this is a “taster plate” of
their total contribution. Contrary to the often held view, glycan
structures frequently bind proteins with quite exquisite speci-
ficity; our lack of understanding of their binding modes and the
nature of the protein conformations that are recognized cause the
miss-interpretation. Reductionist thinking and analyses, although
useful, in isolation are unlikely to reveal the truth. Repeatedly,
it is the “context,” whether the presentation of glycan motifs,
or the molecules (proteins and carbohydrates) of the surround-
ing microenvironment, which determines the outcome of gly-
can–protein interactions. It is fitting that the concluding article
in this series (20) describes the development of a glycan inspired
potential therapeutic, because this is an area of drug discovery cur-
rently under exploited. Advances in technologies of glycan struc-
ture determination and syntheses, coupled with a more holistic
approach to understanding glycan interactions with their binding
partners will lead to more glycan inspired therapeutics to treat
immunological diseases.
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